Welcome!

News Feed Item

Tresiba®▼ (insulin degludec) - a new basal insulin for adult patients with type 1 and type 2 diabetes is available in the UK as a new treatment option

CRAWLEY, UK, March 4, 2013 /PRNewswire/ --

Insulin degludec is indicated for the treatment of diabetes mellitus in adults[1].

Novo Nordisk UK has announced that insulin degludec (brand name Tresiba®), a new once-daily basal insulin for adult patients with type 1 and type 2 diabetes, is available in the UK as a new treatment option.

Insulin degludec effectively reduces blood glucose levels in patients with type 1 and 2 diabetes[2],[3] while significantly reducing the risk of night-time hypoglycaemia, compared with the most commonly prescribed basal insulin in the UK[4]:

  • 25% reduction in night-time hypoglycaemia for patients with type 1 diabetes [4.41 vs 5.86 episodes per patient year of exposure (PYE); p=0.02][3]
  • 36% reduction in night-time hypoglycaemia for insulin naïve patients with type 2 diabetes [0.25 vs 0.39 episodes per PYE; p<0.04][2]
  • There was no significant difference in the rate of confirmed overall hypoglycaemic episodes for insulin degludec versus insulin glargine in patients with type 1 diabetes (42.54 vs 40.18 episodes per patient year of exposure p=0.48)[3] or for insulin naïve patients with type 2 diabetes (1.52 vs 1.85 per patient year of exposure; p=0.11)[2]

Insulin degludec is a once-daily basal insulin which can be administered at any time of the day, however preferably at the same time every day. It is the first insulin to offer people with diabetes the flexibility in the timing of insulin administration on occasions when administration at the same time of day is not possible. A minimum of eight hours between injections should always be ensured[1],[5].


"Many of my patients tell me when I see them in clinic that they have difficulty taking their insulin at exactly the same time each day. This is often for reasons which we can all sympathise with and understand. For example picking children up from school or working irregular shifts at work. It is thus very useful that there is now an insulin which, because of its longer duration of action, is able to offer patients a bit more flexibility in terms of timing of their dose without compromising either their glycaemic control or risk of hypoglycaemia", commented Professor Melanie J Davies, Professor of Diabetes Medicine, University of Leicester and Honorary Consultant, University Hospitals of Leicester.

Hypoglycaemic episodes are one of the most common side effects of insulin treatment[6], and although insulin degludec significantly reduces night-time hypoglycaemia, hypoglycaemia is still the most frequent side effect[1]. However, of particular concern is the risk of night-time hypoglycaemia; often when the patient is sleeping and therefore less aware of the onset of symptoms[7].

While reduced risk of hypoglycaemia has obvious benefits for the person with diabetes, it is also important for society in general. The economic impact of hypoglycaemia in the UK is particularly significant[8]. In 2010/11, the estimated UK cost for severe hypoglycaemia was £30.4 million and for moderate hypoglycaemia £41.8 million[8]. Each severe hypoglycaemic episode involving hospitalisation, costs the NHS an estimated £2,153 per person[9],[10]. Almost 50% of severe hypoglycaemic episodes occur at night and the most severe night-time episodes can be fatal if left untreated[7]. Severe episodes are estimated to be responsible for 6% of deaths in people with diabetes under the age of 40[7],[11].

Insulin degludec is available in two FlexTouch® pens: FlexTouch® U100, which is suitable for doses from 1 to 80 units per injection and dials in one unit increments, and FlexTouch® U200, which allows up to 160 units of insulin in one injection and dials in two unit increments. The U200 is the first prefilled pen that allows patients who need more than 80 units of basal insulin each day to inject only once.  

"Novo Nordisk has a long heritage in changing the diabetes landscape with 90 years of innovation and leadership in diabetes care. Our focus is in developing treatments that address key challenges faced by patients and clinicians," said Peter Meeus, UK/IRE Managing Director, Novo Nordisk.

- ENDS -

Notes to Editors

About Tresiba® (insulin degludec)

Insulin degludec is a new once-daily basal insulin for adults with diabetes, discovered and developed by Novo Nordisk. Insulin degludec reduces blood glucose levels with a lower risk of night-time hypoglycaemia compared to insulin glargine[1]. Furthermore, insulin degludec provides a duration of action beyond 42 hours[1], allowing for flexibility in day-to-day dosing time when needed (minimum of 8 hours between injections)[1]. Insulin degludec is available in FlexTouch®, Novo Nordisk's latest prefilled insulin pen, and is offered in two concentrations enabling maximum doses of up to 80 and 160 units per single injection. Insulin degludec is also available in a cartridge (Tresiba® Penfill®), designed to be used with Novo Nordisk insulin delivery systems.

Insulin degludec was approved for use in type 1 and type 2 diabetes on 21 January 2013 by the European Commission.

Indication: Insulin degludec is indicated for the treatment of diabetes mellitus in adults[1].

Safety: The most frequent side effects are hypoglycaemia and injection site reactions[1]. Hypoglycaemia is the most frequently reported adverse reaction during treatment (very common, ≥1/10)[1]. Injection site reactions are usually mild and transitory and normally disappear during continued use (common, ≥1/100 to <1/10)[1]. Insulin degludec has been studied in a clinical trial programme involving more than 7,000 people with diabetes[12].

See the Summary of Product Characteristics (SmPC) for further information.

About diabetes

Diabetes (or diabetes mellitus) is a serious and challenging health condition that develops when there is too much sugar in the blood due to the body being unable to produce or respond to the hormone, insulin, in the normal way[13]. Every three minutes, one person in the UK is diagnosed with diabetes[14], and approximately 2.9 million people have already been diagnosed with diabetes in the UK. This figure is projected to rise to 5 million by 2025[14].

About hypoglycaemia

Hypoglycaemia is an episode of low blood sugar which may lead to accidents, injuries and even death in severe cases[15],[16]. It is estimated that 6% of diabetes-related deaths are linked to severe hypoglycaemic episodes[17]. Despite advances in insulin therapy, the risk of hypoglycaemia remains a serious problem. Severe hypoglycaemic episodes (where assistance from another person is required and may result in hospitalisation) can lead to seizures, coma and even death if left untreated[18]. Even non-severe hypoglycaemic episodes have a large impact on daily life for many people with diabetes, including lost productivity at work[19]. People with type 1 diabetes suffer, on average, over three episodes per month (42.9 episodes per year). People with type 2 diabetes suffer, on average, over one episode per month (16.4 episodes per year)[20]. These episodes cause many people with diabetes and their relatives to live with the fear of the next episode every day[6].


About Novo Nordisk

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.co.uk.

® Tresiba®, FlexTouch®, Penfill® and the APIS bull are trademarks owned by Novo Nordisk A/S.

References

  1. Tresiba® summary of product characteristics 2013.
  2. Zinman B et al., Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long) Diabetes Care. 2012;35(12):2464-71.
  3. Heller S et al., Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3 randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1489-1497.
  4. Ratner RE et al., Prospectively planned meta-analysis comparing hypoglycemia rates of insulin degludec with those of insulin glargine. Diabetes, Obesity and Metabolism. 2013;15(2):175-184.
  5. Meneghini L et al., The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in people with type 2 diabetes. Diabetes Care. 2013 [epub ahead of print] dow: 10.2337/dc12-1668.
  6. Leiter LA et al., Assessment of the Impact of Fear of Hypoglycemic Episodes on Glycemic and Hypoglycemia Management. Can J Diabetes. 2005;29:186-92.
  7. Allen KV et al.,  BM. Nocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward prevention. Endocr Pract. 2003;9(6):530-43.
  8. Hex N et al., Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855-62.
  9. ISD Scotland. Available at URL: http://www.isdscotland.org/Health-Topics/Finance/Publications/2011-11-29/Costs_R910_2011.xls Last accessed: February 2013.
  10. Department of Health. Payment by results tariffs. Available at URL: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_124356 Last accessed: February 2013.
  11. Sovik O et al., Dead-in-bed syndrome in young diabetic patients. Diabetes Care. 1999;22(S2):B40-2.
  12. Novo Nordisk data on file. DOF-IDeg-130712-005.
  13. NHS Choices. Diabetes introduction.  Available at URL: http://www.nhs.uk/Conditions/Diabetes/Pages/Introduction.aspx Last accessed: February 2013.
  14. Diabetes UK. State of the Nation 2012. Available at URL: http://www.diabetes.org.uk/Documents/Reports/State-of-the-Nation-2012.pdf Last accessed: February 2013.
  15. Cefalu CA et al., Controlling hypoglycemia in type 2 diabetes: which agent for which patient? J Fam Pract. 2005;54:855-62.
  16. American Diabetes Association Working Group on Hypoglycemia. Defining and reporting hypoglycemia in diabetes. Diabetes Care. 2005;28:1245-9.
  17. Bonds DE et al., The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:B4909.
  18. Briscoe VJ et al., Hypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology and management. Clin Diabetes. 2006;24:115-21.
  19. Brod M et al., The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71.
  20. Donnelly LA et al., Frequency and Predictors of Hypoglycaemia in Type 1 and Insulin-Treated Type 2 Diabetes: A Population-Based Study. Diabet Med. 2005;22:749-55.


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, provided a fun and simple way to introduce Machine Leaning to anyone and everyone. He solved a machine learning problem and demonstrated an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intelligence and B...
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software. They hope to capture value from emerging technologies such as IoT, SDN, and AI. Ultimately, irrespective of the vertical, it is about deriving value from independent software applications participating in an ecosystem as one comprehensive solution. In his session at @ThingsExpo, Kausik Sridhar, founder and CTO of Pulzze Systems, discussed how given the magnitude of today's application ...
DevOps promotes continuous improvement through a culture of collaboration. But in real terms, how do you: Integrate activities across diverse teams and services? Make objective decisions with system-wide visibility? Use feedback loops to enable learning and improvement? With technology insights and real-world examples, in his general session at @DevOpsSummit, at 21st Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, explored how leading organizations use data-driven DevOps to clos...
The 22nd International Cloud Expo | 1st DXWorld Expo has announced that its Call for Papers is open. Cloud Expo | DXWorld Expo, to be held June 5-7, 2018, at the Javits Center in New York, NY, brings together Cloud Computing, Digital Transformation, Big Data, Internet of Things, DevOps, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
Nordstrom is transforming the way that they do business and the cloud is the key to enabling speed and hyper personalized customer experiences. In his session at 21st Cloud Expo, Ken Schow, VP of Engineering at Nordstrom, discussed some of the key learnings and common pitfalls of large enterprises moving to the cloud. This includes strategies around choosing a cloud provider(s), architecture, and lessons learned. In addition, he covered some of the best practices for structured team migration an...
Mobile device usage has increased exponentially during the past several years, as consumers rely on handhelds for everything from news and weather to banking and purchases. What can we expect in the next few years? The way in which we interact with our devices will fundamentally change, as businesses leverage Artificial Intelligence. We already see this taking shape as businesses leverage AI for cost savings and customer responsiveness. This trend will continue, as AI is used for more sophistica...
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, discussed how they built...
The “Digital Era” is forcing us to engage with new methods to build, operate and maintain applications. This transformation also implies an evolution to more and more intelligent applications to better engage with the customers, while creating significant market differentiators. In both cases, the cloud has become a key enabler to embrace this digital revolution. So, moving to the cloud is no longer the question; the new questions are HOW and WHEN. To make this equation even more complex, most ...
As you move to the cloud, your network should be efficient, secure, and easy to manage. An enterprise adopting a hybrid or public cloud needs systems and tools that provide: Agility: ability to deliver applications and services faster, even in complex hybrid environments Easier manageability: enable reliable connectivity with complete oversight as the data center network evolves Greater efficiency: eliminate wasted effort while reducing errors and optimize asset utilization Security: imple...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, examined the regulations and provided insight on how it affects technology, challenges the established rules and will usher in new levels of diligence arou...
The past few years have brought a sea change in the way applications are architected, developed, and consumed—increasing both the complexity of testing and the business impact of software failures. How can software testing professionals keep pace with modern application delivery, given the trends that impact both architectures (cloud, microservices, and APIs) and processes (DevOps, agile, and continuous delivery)? This is where continuous testing comes in. D
Modern software design has fundamentally changed how we manage applications, causing many to turn to containers as the new virtual machine for resource management. As container adoption grows beyond stateless applications to stateful workloads, the need for persistent storage is foundational - something customers routinely cite as a top pain point. In his session at @DevOpsSummit at 21st Cloud Expo, Bill Borsari, Head of Systems Engineering at Datera, explored how organizations can reap the bene...
Digital transformation is about embracing digital technologies into a company's culture to better connect with its customers, automate processes, create better tools, enter new markets, etc. Such a transformation requires continuous orchestration across teams and an environment based on open collaboration and daily experiments. In his session at 21st Cloud Expo, Alex Casalboni, Technical (Cloud) Evangelist at Cloud Academy, explored and discussed the most urgent unsolved challenges to achieve f...